Psoriatic arthritis   

How do you view it relative to existing options like TNFi, IL-23, or IL-17s like ixekizumab?

For example, in patients with many swollen/tender joints, enthesitis, nail involvement do you expect particularly good response? Are there patients in...

How will you counsel patients about the risk and what strategies will you use to mitigate the increased risk of fungal infections see in the BE COMPLE...

The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.

Is there any concern for drug interactions of DMARDs and/or biologics with anti seizure medications?

Given the drug-drug interaction, do you monitor more closely for methotrexate toxicity, counsel on symptoms of methotrexate toxicity, or avoid the com...

What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?

What imaging modality would be most helpful?

Assuming no symptoms of TB, should patients be treated for latent TB prior to starting TNF inhibitors or other immunosuppressive agents?

 Patient is on antibiotics for chronic spinal hardware infection.

In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...

In clinical practice continued steroid dependence is often seen as a reason to switch therapy and providers can be especially hesitant to use systemic...

Based on the results of the DISCOVER-2 Trial (McInnes et al., PMID 34719872), should guselkumab be used prior to anti-TNF therapy in these patients?

In patients refractory to NSAIDs and sulfasalazine